News

Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q2 Sales Beat Estimates But Stock Drops 13.5%

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with ...
Zacks.com on MSN13h

Compared to Estimates, Vertex (VRTX) Q2 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Vertex (VRTX) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to ...

Vertex reiterates $11.85B–$12B 2025 revenue guidance while boosting JOURNAVX commercial investment

Discover how Vertex Pharmaceuticals achieved 12% Q2 2025 revenue growth with new launches like ALYFTREK, CASGEVY, & JOURNAVX.